Skip to main content
. 2019 Nov 13;2019:4038619. doi: 10.1155/2019/4038619

Figure 4.

Figure 4

Anti-TNF-α mAb therapy downregulates hepcidin expression in CD patients. 32 patients with A-CD were treated with anti-TNF-α mAb (infliximab, IFX) at weeks 0, 2, and 6. Serum samples were collected from these patients prior to and 12 weeks after the first anti-TNF-α mAb therapy; the levels of hepcidin in the Response group ((a), n = 19) and the Failure group ((b), n = 13) were analyzed by an ELISA. ∗∗P < 0.01. Unpaired Student's t-tests were performed for statistical analysis.